The development and approval of medicines are supported by extensive clinical research designed to demonstrate safety, efficacy, and quality before a product reaches the market. However, once medicines begin to be used by larger and more diverse patient populations, additional information becomes available that can further enhance understanding of how treatments perform in everyday healthcare settings. This information is commonly referred to as real-world evidence (RWE).
Real-world evidence is generated from data collected outside of traditional clinical trials. Sources may include patient registries, electronic health records, pharmacy dispensing data, health insurance claims, disease surveillance systems, and post-market safety reports. Unlike clinical trials, which are conducted under controlled conditions with carefully selected patient populations, real-world data reflects how medicines are used in routine practice across different ages, backgrounds, healthcare settings, and treatment pathways.
The increasing use of real-world evidence is helping healthcare stakeholders gain a broader understanding of treatment outcomes. It can provide insights into medicine utilisation patterns, adherence rates, long-term safety profiles, and the effectiveness of therapies across larger patient populations. These insights complement clinical trial data and contribute to a more comprehensive picture of how medicines perform over time.
For regulatory authorities, real-world evidence has become an important component of post-market monitoring. Safety information collected through pharmacovigilance systems and other real-world data sources can help identify rare adverse events that may not have been detected during pre-approval studies. This ongoing monitoring supports evidence-based regulatory decision-making and contributes to maintaining confidence in approved medicines.
Healthcare providers also benefit from access to real-world evidence. Information on treatment outcomes and utilisation patterns can help inform clinical decision-making and support the development of treatment guidelines. In some therapeutic areas, particularly those involving chronic diseases, long-term data can provide valuable insight into how medicines perform across different patient groups and healthcare environments.
The relevance of real-world evidence is growing in areas such as biologics and biosimilars, where ongoing monitoring contributes to understanding long-term safety and effectiveness. As these medicines are used more widely, real-world data can help strengthen the evidence base supporting their use and provide additional information for healthcare professionals and patients.
Advances in digital health technologies are further expanding the availability of real-world data. Electronic health records, digital prescribing systems, and integrated healthcare databases allow information to be collected and analysed more efficiently than in the past. These developments are creating new opportunities to identify trends, monitor outcomes, and support healthcare planning.
Importantly, real-world evidence does not replace clinical trials. Instead, it serves as a complementary source of information that extends understanding beyond the controlled environment of pre-approval research. Together, clinical trial data and real-world evidence provide a more complete understanding of medicine performance throughout its lifecycle.
As healthcare systems continue to evolve, the role of data in supporting decision-making is becoming increasingly important. Real-world evidence provides an additional layer of insight that can support regulators, healthcare providers, manufacturers, and policymakers in understanding how medicines are used and how they contribute to patient outcomes. By transforming routine healthcare information into actionable knowledge, real-world evidence is becoming an increasingly valuable tool in the ongoing effort to improve healthcare delivery and patient care.